Posts

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

on

Assembly Biosciences Completes $115 Million Stock and Warrant Offering With Full Underwriters Option Exercise

on

Gilead Declines Option on Assembly Biosciences' Phase 1 HBV Antiviral ABI-4334

on

Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration

on

Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study

on

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

on

Neurocrine Biosciences Reports Positive Phase 2 Results for Osavampator in Major Depressive Disorder

on

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

on

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA

on

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

on

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

on

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

on

Ascletis' Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

on

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

on

Daiichi turns to Nosis for AI-designed RNA delivery tech

on

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

on

Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years

on